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Olfactory discrimination predicts cognitive decline
among community-dwelling older adults
HR Sohrabi1,2,3, KA Bates2,3,4, MG Weinborn5, ANB Johnston6, A Bahramian2, K Taddei1,2,3, SM Laws1,2,3, M Rodrigues1,2,
M Morici1, M Howard1, G Martins1,2, A Mackay-Sim6, SE Gandy7 and RN Martins1,2,3,8

The presence of olfactory dysfunction in individuals at higher risk of Alzheimer’s disease has significant diagnostic and screening
implications for preventive and ameliorative drug trials. Olfactory threshold, discrimination and identification can be reliably
recorded in the early stages of neurodegenerative diseases. The current study has examined the ability of various olfactory
functions in predicting cognitive decline in a community-dwelling sample. A group of 308 participants, aged 46–86 years old, were
recruited for this study. After 3 years of follow-up, participants were divided into cognitively declined and non-declined groups
based on their performance on a neuropsychological battery. Assessment of olfactory functions using the Sniffin’ Sticks battery
indicated that, contrary to previous findings, olfactory discrimination, but not olfactory identification, significantly predicted
subsequent cognitive decline (odds ratio ¼ 0.869; Po0.05; 95% confidence interval ¼ 0.7640.988). The current study findings
confirm previously reported associations between olfactory and cognitive functions, and indicate that impairment in olfactory
discrimination can predict future cognitive decline. These findings further our current understanding of the association between
cognition and olfaction, and support olfactory assessment in screening those at higher risk of dementia.
Translational Psychiatry (2012) 2, e118; doi:10.1038/tp.2012.43; published online 22 May 2012

Introduction
Olfactory dysfunction has been reliably demonstrated in
Alzheimer’s disease (AD)1–3 and mild cognitive impairment.4,5
Of note, olfactory impairment has also been reported in
cognitively healthy individuals positive for apolipoprotein E e4
(APOE-e4) allele, the main genetic risk factor for AD,6,7 as well
as in those with another potential risk factor for AD, namely
subjective memory complaints.8
Indeed, olfactory dysfunction has been significantly associated with the risk of future AD and AD neuropathology burden
in the brain.9 AD-related neuropathological studies of animals
and humans have indicated the following: (i) A negative
association between amyloid-beta (b-amyloid) load in the brain
and olfaction;10–12 (ii) A strong association between tau
pathology in olfactory system, Braak staging of AD pathology
and cognitive decline;13,14 and (iii) Presence of oxidative
damage in the olfactory epithelium in the early stages of
AD.15,16
Observational and clinical studies have found a significant
association between olfactory impairment and subsequent
cognitive decline. For example, a large-scale study (N ¼ 1920)
on the relationship between olfactory identification ability and
general cognitive functioning (as measured by Mini Mental
State Examination (MMSE)) indicated that olfactory dysfunction at baseline was significantly predictive of future cognitive
impairment after 5 years (odds ratio (OR) ¼ 6.62; confidence

interval (CI) ¼ 4.36–10.04).17 Schubert et al.17 have also
reported low sensitivity of 55.1% but high specificity (84.4%)
for olfactory assessment in predicting cognitive decline.
However, the olfaction/cognition relationship has not been
consistently found, particularly when more complicated
olfactory assessment instruments including electrophysiological measures were used in addition to psychophysical
methods.18 Indeed, the different methods utilized to assess
olfaction may be responsible for the inconsistent findings.19
Olfactory abilities are primarily assessed by measuring
threshold (lowest detectable concentration of odors), discrimination (ability to differentiate between odors) and identification (ability to identify odors).20 It has been suggested that
olfactory threshold is strongly related to sensory capability,
while olfactory discrimination and identification are more
closely associated with higher cognitive functions, and thus
may be more cognitively loaded.8,21 A dated, but still
informative, review has reported a strong association between
cognitive functions and certain aspects of olfactory functioning, concluding that compared with the ability to detect odors,
identification of odors is more challenging, perhaps due to a
lack of access to verbal or visual representations of odors.22
Similarly, Schab23 noted that odor identification may represent a semantic memory function. Some researchers suggest
that olfactory identification is primarily predictive of memory
decline.24 It is interesting that while verbal and visual cues
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may affect olfactory information processing, olfactory memories usually last longer than memories formed through other
sensory modalities and have more emotional valence.25,26
There is strong evidence that neuroanatomical regions
involved in episodic memory, including the medial temporal
lobe, are also associated with olfactory functioning.27,28
Interestingly, individuals with hippocampal lesions show
significantly poorer olfactory recognition compared with odor
threshold.29
Olfactory impairment is not confined to people with AD or
AD-related cognitive decline, and it has been reported in
individuals suffering from other neurodegenerative diseases
such as Parkinson’s disease, frontotemporal dementia and
Lewy body dementia.30–32 Olfactory deficits have also been
reported in psychiatric disorders including schizophrenia and
depression.33,34 As such, olfactory dysfunctions appear not to
be specific to AD.35,36 Further studies are needed to improve
the sensitivity and specificity of olfactory screening to identify
which olfactory domains are specifically affected at particular
stages of preclinical AD.
We hypothesized that olfactory ability at baseline could
predict altered cognitive function in a 3-year follow-up
assessment. The specific questions examined by the current
study were the following: (1) Is there any association between
olfaction and cognition at baseline in this cohort of apparently
healthy aging individuals? (2) Could baseline olfactory
function predict future (3-year) cognitive decline? (3) Which
olfactory domain(s) best predict cognitive alteration?
Materials and methods
Design. Participants were derived from a larger, longitudinal
study, ‘the Western Australia Memory Study’ (for more
information on this cohort, see refs 8,37–39). Participants
were monitored for 3 years, and underwent annual neuropsychological, biochemical and physiological examinations.
Herein, the baseline and final assessment (two-point data)
results of this study will be examined. The study was
approved by the Human Research Ethics Committees of
the associated institutions, namely the University of Western
Australia, Edith Cowan University and Hollywood Private
Hospital. Participants provided informed consent before
baseline assessments according to the guidelines of the
National Health and Medical Research Council of Australia.

capacities (for example, sinunasal diseases, upper respiratory tract infection, severe head injury, Parkinson’s disease,
schizophrenia, and so on).
Measures. Olfactory function was assessed using the
‘Extended Sniffin’ Sticks’ battery (Burghart, Wedel, Germany), in which odors are presented using felt-tip pen-like
sticks.42 The Extended Sniffin’ Sticks assess three domains of
olfactory function, using threshold (T), discrimination (D) and
identification (I) as three subscales and enabling calculation of
a composite score, namely TDI.43,44 In this study, the Sniffin’
Sticks battery was administered in a triple forced-choice
staircase method as outlined previously45 and also in the test
manual (Burghart).
The CAMCOG-R46 and MMSE40 were used to assess
general cognitive functioning. The CAMCOG-R measures
orientation, language, memory, attention, abstract thinking,
praxis and calculation abilities, and provides a total score of
cognitive functioning. The MMSE is commonly used as a
screening measure to assess general cognitive performance
in clinical and research settings.47
APOE genotyping. Blood samples were collected into
different blood collection tubes including serum, EDTA
(containing prostaglandin E) and heparin (Interpath Services,
West VIC, Australia). The DNA was isolated from leukocytes,
and APOE genotype was determined using PCR amplification
and restriction enzyme digestion as previously described.48,49
Statistical analysis. All statistical analyses were performed
using PASW Statistics 18 for Windows 7. Partial correlation
was applied to control for the effects of age. Variables
examined in this study including sex, APOE genotype, age at
baseline, baseline cognitive function and olfactory
performance, as measured by Sniffin’ Sticks, were entered
in a logistic regression model using the enter analysis model.
After the completion of 3-year follow-up, participants were
divided into two groups: cognitively declined and nondeclined. Participants were considered to be ‘cognitively
declined’ if their score on the final cognitive assessment (as
measured by CAMCOG-R) was X1 s.d. below their baseline
performance.
Results

Participants. A total of 308 community-dwelling older adults
aged 46–86 years old (68% female) were recruited from a
larger study cohort. The volunteers’ family members were
also invited to participate. The APOE-e4 genotype was
available for 273 participants, of whom 34% were e4 allele
carriers (e2-e4, e3-e4, or e4-e4). The mean education level for
the cohort was 13.5 years (±3.77), and inclusion criteria
were a minimum of 6 years of education, age 45 and over,
and fluency in English. Exclusion criteria for this study
included: (i) a baseline score of p24 in MMSE40 and p81 in
the Cambridge Cognitive Examination-Revised (CAMCOGR);41 (ii) history of anosmia or any known olfactory problems;
and (iii) history or formal diagnosis of medical, neurological
or psychiatric diseases and disorders affecting olfactory
Translational Psychiatry

Cohort demographics. For this study, 308 participants with
a mean age of 63.06 (±7.25) years undertook neuropsychological testing. Demographic characteristics of the cohort are
shown in Table 1. The scores of male/female and APOE-e4
carrier and non-carrier groups on the MMSE, Sniffin’ Sticks
and CAMCOG-R at baseline (Table 1) were all above the
cutoff scores, as required in the exclusion criteria (40,41,50,
respectively).
Mackay-Sim et al.51 provide guidelines for the classification
of differing levels of olfactory impairment using Sniffin’ Sticks:
(1) severe hyposmia (a score of p23 on Sniffin’ Sticks TDI for
women and p21 for men); (2) anosmia (a TDI score of p16);
and (3) mild hyposmia (in women a score of 23–27, and in men
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Table 1 Baseline descriptive results (age, years of education, cognitive measures and olfactory function were assessed and data analyzed in terms of gender and
APOE genotype; Total N ¼ 308)

Variables
Age
Education years
MMSE
CAMCOG-R
SS-T
SS-D
SS-I
SS-TDI

Male
( N ¼ 99)

Female
( N ¼ 209)

P

APOE-e4 a
non-carrier ( N ¼ 202)

APOE-e4 carrier
( N ¼ 99)

P

Total cohort

65.19 (±7.59)
14.05 (±4.14)
29.05 (±1.12)
98.58 (±3.58)
7.03 (±2.58)
11.31 (±2.25)
12.64 (±1.80)
30.67 (±4.53)

62.05 (±6.88)
13.34 (±3.56)
29.20 (±1.09)
98.71 (±3.34)
7.58 (± 2.34)
11.88 (±2.43)
12.49 (±2.04)
31.72 (±4.63)

0.000*
0.127
0.281
0.743
0.063
0.058
0.539
0.061

63.43 (±7.62)
13.58 (±3.91)
29.16 (±1.17)
98.75 (±3.50)
7.44 (±2.35)
11.83 (±2.37)
12.54 (±1.98)
31.54 (±4.58)

62.70 (±6.39)
13.41 (±3.43)
29.11 (±0.96)
98.49 (±3.12)
7.30 (±2.09)
11.49 (±2.41)
12.56 (±1.80)
31.08 (±4.53)

0.413
0.713
0.729
0.536
0.622
0.260
0.919
0.414

63.06 (±7.25)
13.57 (±3.77)
29.15 (±1.10)
98.67 (±3.41)
7.40 (±2.37)
11.69 (±2.39)
12.54 (±1.96)
31.38 (±4.62)

Abbreviations: CAMCOG-R, The Revised Cambridge Cognitive Examination; MMSE, Mini Mental State Examination; SS-D, Sniffin’ Sticks discrimination; SS-I,
Sniffin’ Sticks identification; SS-T, Sniffin’ Sticks threshold; SS-TDI, Sniffin’ Sticks composite score.
a
Apolipoprotein E e4 allele. *Pp0.05.
Table 2 Demographic information and baseline performance of cognitively declineda and non-declined participants

Age

Educ. years b

62.59 (±6.98)

13.65 (±3.65)

65.10 (±8.08)

13.22 (±4.25)

Variables
Non-declined
(N ¼ 250)
Declined
(N ¼ 58)
P

0.017*

MMSE

SS-T

SS-D

SS-I

SS-TDI

29.20 (±1.11) 98.63 (±3.28)

7.53 (±2.32)

11.90 (±2.21)

12.62 (±1.91)

31.79 (±4.13)

28.95 (±1.05) 98.84 (±3. 94)

6.87 (±2.55)

10.80 (±2.86)

12.20 (±2.16)

29.65 (±6.04)

0.153

0.013*,

0.442

CAMCOG-R

0.124

0.664

0.063

,c

0.009*

c

Abbreviations: CAMCOG-R, The Revised Cambridge Cognitive Examination; MMSE, Mini Mental State Examination; SS-D, Sniffin’ Sticks discrimination; SS-I,
Sniffin’ Sticks identification; SS-T, Sniffin’ Sticks threshold; SS-TDI, Sniffin’ Sticks composite score.
a
Cognitive decline was considered as a score X1 s.d. below baseline performance on CAMCOG-R in the last assessment. bEducation years. cEqual variance not
assumed. *Pp0.05.
Table 3 Prediction of cognitive declinea using Sniffin’ Sticks discrimination in multiple logistic regression analysis (N ¼ 282)b

Factors

Sex
APOE genotypes
Age at baseline
Education years
MMSE
SS-D

B

0.005
0.518
0.031
0.008
0.140
0.141

s.e.

0.340
0.323
0.023
0.042
0.132
0.066

Wald

0.000
2.579
1.846
0.039
1.119
4.582

df

1
1
1
1
1
1

P*

0.988
0.108
0.174
0.843
0.290
0.032*

OR

0.995
0.596
1.035
0.992
0.870
0.869

95% CI for OR
Lower

Upper

0.511
0.316
0.986
0.912
0.617
0.764

1.937
1.121
1.078
1.078
1.127
0.988

Abbreviations: CAMCOG-R, The Revised Cambridge Cognitive Examination; CI, confidence interval; MMSE, Mini Mental State Examination; OR, odds ratio; SS-D,
Sniffin’ Sticks discrimination.
a
Cognitive decline was considered as a score X1 s.d. below baseline performance on the CAMCOG-R in the last assessment. bN was 308; however, only 282 were
entered in the actual analysis. *Po 0.05.

a score of 21–29). In our cohort, 6.5, 1.3 and 19.5% met these
criteria, respectively.
In this cohort, 194 (62.98) participants were non-smokers,
105 (34.09) were ex-smokers (with at least 2 years of
abstinence) and 9 (2.93) participants were smokers. However,
as there were no significant differences between the nonsmokers and other groups in any of the baseline assessments
including age, education, cognitive function (as assessed by
MMSE and CAMCOG-R) and olfactory assessments, we did
not include smoking as a factor in this study.
Cognitive performance over time. There was no
significant association between sex and cognitive decline
(w2(1) ¼ 0.179, P ¼ 0.672) or APOE genotypes and cognitive
decline (w2(1) ¼ 1.773, P ¼ 0.183). Participants who were
classified as declined (n ¼ 58) performed more poorly on
olfactory discrimination (t ¼ 3.14; df ¼ 286; Po0.05) and on
cumulative olfactory performance (t ¼ 1.33; df ¼ 306; Po.05)

as measured by Sniffin’ Sticks TDI (Table 2). The declined
group was older at baseline as compared with non-declined
group (N ¼ 250; t ¼ 2.39; df ¼ 306; Po0.05), but did not
differ on other demographic variables including education
and cognitive functioning as measured by MMSE and
CAMCOG-R.
Analysis of the association between the variables indicated
that age was negatively associated with baseline CAMCOG-R
(r ¼ 0.171; Po0.01), Sniffin’ Sticks T (r ¼ 0.193; Po0.01),
D (r ¼ 0.260; Po0.01), I (r ¼ 0.188; Po0.01) and TDI
(r ¼ 0.296; Po0.01). The CAMCOG-R was significantly
associated with baseline Sniffin’ Sticks D (r ¼ 0.253; Po0.01),
I (r ¼ 0.271; Po0.01) and TDI (r ¼ 0.228; Po0.01), but not
with Sniffin’ Sticks T (r ¼ 0.006; Po0.92). To control the
effects of age on the associations between various variables,
partial correlation was performed. Partial correlation analysis
indicated that even after controlling for the effects of age,
baseline CAMCOG-R was still significantly associated with
Translational Psychiatry
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Table 4 Predictors of cognitive declinea using Sniffin’ Sticks total, composite score in multiple logistic regression analysis (N ¼ 282)b

Factors

Sex
APOE genotypes
Age at baseline
Education years
MMSE
SS-TDI

B

0.095
0.442
0.034
0.008
0.158
0.073

s.e.

0.333
0.316
0.022
0.042
0.130
0.033

Wald

0.082
1.964
2.296
0.035
1.482
4.842

df

P*

1
1
1
1
1
1

OR

0.775
0.161
0.130
0.851
0.223
0.028*

95% CI for OR

1.100
0.642
1.035
0.992
0.852
0.930

Lower

Lower

0.572
0.346
0.990
0.914
0.663
0.872

2.113
1.193
1.081
1.077
1.101
0.992

Abbreviations: CAMCOG-R, The Revised Cambridge Cognitive Examination; CI, confidence interval; MMSE, Mini Mental State Examination; OR, odds ratio; SS-TDI,
Sniffin’ Sticks composite score.
a
Cognitive decline was considered as a score X1 s.d. below baseline performance on the CAMCOG-R in the last assessment. bN was 308; however, only 282 were
entered in the actual analysis. *Po0.05.

Discussion
The major novel finding of the current study was that olfactory
discrimination (as measured by Sniffin’ Sticks D) was a
significant predictor of future cognitive decline over a 3-year
period. The study also confirmed a series of existing findings,
demonstrating that age is associated with both cognitive and
olfactory functions. However, there was a significant association between olfactory function and cognitive performance
even after controlling for the effects of age, education years,
APOE genotype and sex. Three olfactory functions including
threshold, discrimination and identification were separately
assessed in this study. Interestingly, we found that discrimination was the best predictor of cognitive decline over time. It
is important to note that the cognitive changes observed were
small and subtle with the study participants performing within
the normal range on cognitive measures.
Interestingly, our findings do not support those of other
researchers who have reported that impaired olfactory identification is a strong predictor of cognitive impairment.52–55
Wilson et al.56 further reported that impairment in olfactory
identification at baseline was significantly associated with the
incidence of mild cognitive impairment. It has been reported
Translational Psychiatry

------- CAMCOG-R total Score; - - - - - SS TDI total Score
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2

CAMCOG-R baseline total score

R Linear =0.029
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R Linear =0.087

95
30.00
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Sniffin' Sticks TDI score- baseline

Sniffin’ Sticks D (r ¼ 0.296, Po0.01), I (r ¼ 0.218, Po0.01) and
TDI (r ¼ 0.277, Po0.01). The association between baseline
olfactory functions with cognitive decline after 3 years was
further explored using logistic regression analysis (Tables 3
and 4). The ‘D’ scale was significantly associated with cognitive
decline (OR ¼ 0.869; Po0.05; 95% CI ¼ 0.7640.988); however, neither ‘T’ (OR ¼ 0.916; Po0.192; 95% CI ¼ 0.803–
1.045) nor ‘I’ (OR ¼ 0.917; Po0.262; 95% CI ¼ 0.787–1.067)
was significantly associated with cognitive decline as defined
by CAMCOG-R performance in the last assessment (Table 3).
Interestingly, baseline cognitive function (as measured by
CAMCOG-R) and olfactory abilities showed similar trend of
decline (Figure 1). However, other factors including sex, APOE
genotype, age at baseline and baseline MMSE score were not
significantly associated with cognitive decline in this study.
Logistic regression analysis indicated that higher Sniffin’
Sticks TDI (composite) score was associated with lower risk of
cognitive decline (OR ¼ 0.872; Po0.05; 95% CI ¼ 0.8720.992)
(Table 4). Other variables, including sex, APOE genotype, age,
education and baseline MMSE score, did not indicate a
significant predictive value with regards to cognitive decline.

20.00
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80
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Figure 1 Dual axes graph showing the association between age, the
CAMCOG-R and the Sniffin’ Sticks composite score. J The Cambridge Cognitive
Examination-Revised (CAMCOG-R) total score; *Sniffin’ Sticks TDI (composite
score). The dual axes graph with linear trend lines shows the baseline performance
on cognitive measure (CAMCOG-R total score) and general olfactory function (as
derived from the Sniffin’ Sticks composite score). Both the CAMCOG-R (upper line)
and SS TDI (below the first line) linear lines show a close trend of decline over time.
The mean scores were used for this graph.

that patients who were anosmic at baseline had twice the risk
of developing AD compared with controls over a 2-year follow
up, and if they had at least one APOE-e4 allele, the risk
increased to 4.9 times.7 It should be noted that while some
researchers report a significant olfactory decline in individuals
positive for APOE-e4 allele,6 others have failed to find this
relationship8,57 and our current findings are consistent with
these latter studies.
The reports on olfactory identification impairments in AD
patients and in individuals at higher risk for pathological
cognitive decline are not conclusive. That is, impairment in
both olfactory identification and threshold have been reported
as predictive of cognitive decline and AD.52,55,58,59 One
potential explanation is odor discrimination is primarily
impaired in AD individuals while identification problems are
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more common among patients with semantic dementia,
frontotemporal dementia or corticobasal dementia.60 Another
explanation for our findings is that previous studies have
focused primarily, often exclusively, on odor identification and
might have not extensively assessed other olfactory domains
including threshold and discrimination.61,62 It has been
suggested that olfactory discrimination, similar to identification, requires higher cognitive functions including working
memory, judgment and decision making, and its dysfunction
may represent generalized cognitive deterioration.63 Our
findings support this interpretation. However, involvement of
hippocampal regions in a network underlying odor discrimination64 increases the probability of a more specific memoryrelated role in discrimination. Clearly, more studies are
needed to clarify the neural regions associated with
odor discrimination and cognition. As demonstrated in the
present study, controlled, systematic evaluation of the
various olfactory domains would contribute to more powerful assessment of the cognitive elements of odor memory
and recognition, and thus also possible links to cognitive
function.
The association of age with both cognitive65 and olfactory25
functions is consistent with the reports indicating that age is a
significant covariate. However, the findings reported in this
study indicate that the association between cognitive functions and olfactory discrimination and identification is independent of the effects of age. It has been argued that the
effects of age on olfaction can be explained by the effects of
cognitive decline, not age or age-related hazards affecting
olfaction.66 Age, per se, may not account for the so-called
age-associated olfactory dysfunction or presbyosmia, as
decline in olfactory function with healthy aging seems much
lower than previously reported.67 Given this, our findings
support previous reports suggesting that cognitive functions,
specifically those with higher verbal component, are significantly associated with olfaction.66,68
Another significant finding was the value of measuring
multiple domains of olfactory functioning in predicting cognitive decline over 3 years in community-dwelling elderly
individuals. Previous reports have mainly focused on the
value of measuring specific olfactory domains such as
identification in predicting pathological or age-related cognitive decline (for examples, see refs 17,56,69). The study
reported here indicated that a comprehensive measure of
olfactory function has significant power in predicting cognitive
decline in healthy individuals. As various olfactory functions
are to some degree reliant on threshold,70 it is necessary to
assess the participants’ olfactory acuity before further
assessment with more specialized measures such as
identification71 that may then be used for differential diagnosis
or screening purposes.
The mechanisms underlying the association between
olfaction and cognition have been extensively examined in
the last 100 years both by psychophysics and neuroanatomical studies (72,73, for a review of earlier work see Herz and
Engen74). For example, psychophysics studies have found
that olfactory identification was significantly associated with
semantic verbal memory, implying that the two may share
some cognitive domains.66,75–77 Neuropathological studies
have revealed that brain regions and subsystems involved in

odor information processing, including the olfactory bulb,
piriform and orbital prefrontal cortices, have direct projections
to perirhinal and entorinal cortices. These, in turn, have
extensive projections to the hippocampus,78–80 known as the
primary brain region involved in initial memory formation,81–83
and also one of the first regions affected in AD neurodegeneration.84,85 In addition, the anterior olfactory nucleus and
olfactory bulb are the two primary brain regions commonly
affected in AD.86,87 Indeed, change in olfactory identification
has been strongly associated with pathological changes in the
medial temporal lobe structures.88 These studies strongly
imply a primary role for olfactory dysfunction as an indicator of
pathological cognitive decline and dementia.
The current study had some limitations that should be
considered when interpreting the findings reported. First,
participants were both physically and cognitively within the
normal range, at least as far as it can be inferred from the
MMSE, CAMCOG-R, years of education and various exclusion criteria applied during the participants recruitment phase.
In addition, the participants were divided into declined/nondeclined groups based on neuropsychological measures and
not a formal diagnostic clinical interview. However, the
CAMCOG-R is a comprehensive measure of cognitive function, and while it cannot be considered as a substitute for
formal clinical evaluation of the participants, it has demonstrated high sensitivity to cognitive decline.89,90 Ideally, any
future research using this cohort will examine the consistency
of the reported results against formal diagnostic criteria. Also,
while this study observed a significant association between
olfactory D and cognitive decline, it did not examine the
underlying mechanisms involved in such a distinctive effect for
odor differentiation as compared with other olfactory functions.
In conclusion, the association between the olfactory
function and ongoing cognitive decline established in this
study provides further evidence in support of the inclusion of a
smell assessment alongside other neuropsychological measures in standard health screens for older adults. Many
studies have reported olfactory impairments both in preclinical
and clinical phases of AD. However, as noted by us and
others, the predictive value of olfactory assessment in
screening those at a higher risk for AD needs further
research91,92 to improve its sensitivity and specificity.
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